Pharmaceutical Business Products

By choosing to tackle unaddressed medical needs, we put ourselves on the path to creating new therapeutic approaches and unprecedented drugs. Our researchers are committed to continuing to take the road less travelled, to develop solutions that only we can create.

Otsuka prescription drugs on the global market

Central Nervous System

Antipsychotic
REXULTI / RXULTI*

*brand name in EU

Antipsychotic
ABILIFY Maintena, a prolonged release aquaeous suspension for intramuscular injection
Antipsychotic
ABILIFY
Pseudobulbar Affect (PBA) agent
NUEDEXTA (sold in the U.S.)
Dopaminergic antiparkinsonian agent Restless legs syndrome agent
Neupro Patch
A therapeutic drug treatment to reduce alcohol consumption
Selincro
Anti-CGRP monoclonal antibody
AJOVY

Oncology

Anticancer agent
(tyrosine kinase inhibitor)
ICLUSIG
Conditioning agent for hematopoietic stem cell transplantation
Busulfex

Cardiovascular and Renal areas

V2-receptor antagonist
Samsca / JINARC* / JYNARQUE**

*brand name outside Japan for ADPKD indication (**brand name in U.S.)

Antiplatelet agent
Pletaal

Gastrointestinal

Anti-gastritis and anti-gastric ulcer agent
Mucosta

Infectious diseases

Antituberculosis drug
DELTYBA

Ophthalmology

Therapeutic agent for dry eye
Mucosta ophthalmic suspension
Antiglaucoma and anti-intraocular hypertension drug
Mikeluna combination ophthalmic solution

Diagnostics

13C-Urea breath agent for diagnosis of H. pylori infection
UBIT tablet

This page introduces medical product information related to Otsuka Pharmaceutical's business.
However, it is not intended to indicate or promote the use of these products.

For a better understanding of how to use our drugs correctly

The images of Otsuka Pharmaceutical products on this page are solely for illustration purposes and in no way are intended as recommendations for their use, an assessment that must be made exclusively in consultation with a physician.

The use and the contents of this website are governed under the laws of Japan.